A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is
Authors' commentary on the article Clinical and economic analysis of effectiveness of Nivolumab (Opdivo®) use as second-line monotherapy in adult patients with advanced renal cell carcinoma after previous systemic therapy
2017. Vol. 13, issue1doaj:61cbf1a2e82946099cdabe1c8c9a2b83 fatcat:hkaawyd3ojgsjohtazwofcyp54